Acadia Pharmaceuticals (ACAD) Long-Term Deferred Tax (2022 - 2026)
Acadia Pharmaceuticals (ACAD) posted quarterly Long-Term Deferred Tax of $249.6 million for Q1 2026, little changed quarter-over-quarter from $249.9 million in Q4 2025.
Acadia Pharmaceuticals (ACAD) Long-Term Deferred Tax (2022 - 2026) Analysis & Trends
Acadia Pharmaceuticals' Long-Term Deferred Tax history runs 5 years deep, the most recent figure standing at $249.6 million for Q1 2026.
- In Q1 2026, Long-Term Deferred Tax changed N/A year-over-year to $249.6 million; the TTM figure through Mar 2026 stood at $249.6 million (changed N/A YoY), while the FY2025 annual figure was $249.9 million, up 2772.17% from the prior year.
- Long-Term Deferred Tax for Q1 2026 stood at $249.6 million, roughly flat from $249.9 million in the prior quarter.
- The five-year high for Long-Term Deferred Tax was $249.9 million in Q4 2025, with the low at $1.2 million in Q4 2022.
- The 5-year median for Long-Term Deferred Tax is $8.7 million (2024), against an average of $103.2 million.
- The sharpest annual moves came in 2024 and 2025: Long-Term Deferred Tax increased 27.94% in 2024, then soared 2772.17% in 2025.
- Acadia Pharmaceuticals' Long-Term Deferred Tax stood at $1.2 million in 2022, then surged by 466.67% to $6.8 million in 2023, then rose by 27.94% to $8.7 million in 2024, then jumped by 2772.17% to $249.9 million in 2025, then fell by 0.1% to $249.6 million in 2026.
- Business Quant data shows ACAD's Long-Term Deferred Tax at $249.6 million in Q1 2026, $249.9 million in Q4 2025, and $8.7 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Acadia Pharmaceuticals | 4.86 Bn | 3.90 Bn | 279.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 240.68 Mn |
| Mar 31, 2026 | 249.62 Mn |
| Dec 31, 2025 | 249.88 Mn |
| Dec 31, 2024 | 8.70 Mn |
| Dec 31, 2023 | 6.80 Mn |
| Dec 31, 2022 | 1.20 Mn |